{"pmid":32422645,"title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.","text":["Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.","SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020(1,2). Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of an individual who was infected with SARS-CoV in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309- and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease.","Nature","Pinto, Dora","Park, Young-Jun","Beltramello, Martina","Walls, Alexandra C","Tortorici, M Alejandra","Bianchi, Siro","Jaconi, Stefano","Culap, Katja","Zatta, Fabrizia","De Marco, Anna","Peter, Alessia","Guarino, Barbara","Spreafico, Roberto","Cameroni, Elisabetta","Case, James Brett","Chen, Rita E","Havenar-Daughton, Colin","Snell, Gyorgy","Telenti, Amalio","Virgin, Herbert W","Lanzavecchia, Antonio","Diamond, Michael S","Fink, Katja","Veesler, David","Corti, Davide","32422645"],"abstract":["SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020(1,2). Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of an individual who was infected with SARS-CoV in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309- and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease."],"journal":"Nature","authors":["Pinto, Dora","Park, Young-Jun","Beltramello, Martina","Walls, Alexandra C","Tortorici, M Alejandra","Bianchi, Siro","Jaconi, Stefano","Culap, Katja","Zatta, Fabrizia","De Marco, Anna","Peter, Alessia","Guarino, Barbara","Spreafico, Roberto","Cameroni, Elisabetta","Case, James Brett","Chen, Rita E","Havenar-Daughton, Colin","Snell, Gyorgy","Telenti, Amalio","Virgin, Herbert W","Lanzavecchia, Antonio","Diamond, Michael S","Fink, Katja","Veesler, David","Corti, Davide"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422645","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1038/s41586-020-2349-y","e_drugs":["Polysaccharides"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667254896791912448,"score":9.490897,"similar":[{"pmid":32155444,"pmcid":"PMC7102599","title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.","text":["Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.","The emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000 deaths. Coronavirus spike (S) glycoproteins promote entry into cells and are the main target of antibodies. We show that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, correlating with the efficient spread of SARS-CoV-2 among humans. We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S1/S2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and SARS-related CoVs. We determined cryo-EM structures of the SARS-CoV-2 S ectodomain trimer, providing a blueprint for the design of vaccines and inhibitors of viral entry. Finally, we demonstrate that SARS-CoV S murine polyclonal antibodies potently inhibited SARS-CoV-2 S mediated entry into cells, indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination.","Cell","Walls, Alexandra C","Park, Young-Jun","Tortorici, M Alejandra","Wall, Abigail","McGuire, Andrew T","Veesler, David","32155444"],"abstract":["The emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000 deaths. Coronavirus spike (S) glycoproteins promote entry into cells and are the main target of antibodies. We show that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, correlating with the efficient spread of SARS-CoV-2 among humans. We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S1/S2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and SARS-related CoVs. We determined cryo-EM structures of the SARS-CoV-2 S ectodomain trimer, providing a blueprint for the design of vaccines and inhibitors of viral entry. Finally, we demonstrate that SARS-CoV S murine polyclonal antibodies potently inhibited SARS-CoV-2 S mediated entry into cells, indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination."],"journal":"Cell","authors":["Walls, Alexandra C","Park, Young-Jun","Tortorici, M Alejandra","Wall, Abigail","McGuire, Andrew T","Veesler, David"],"date":"2020-03-11T11:00:00Z","year":2020,"_id":"32155444","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.1016/j.cell.2020.02.058","keywords":["sars-cov","sars-cov-2","antibodies","coronavirus","cryo-em","neutralizing antibodies","spike glycoprotein","viral receptor"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490664910848,"score":506.63315},{"pmid":32454513,"title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection.","text":["Human neutralizing antibodies elicited by SARS-CoV-2 infection.","The emerging coronavirus SARS-CoV-2 pandemic presents a global health emergency in urgent need of interventions(1-3). SARS-CoV-2 entry into the target cells depends on binding between the receptor-binding domain (RBD) of the viral Spike protein and the ACE2 cell receptor(2,4-6). Here, we report the isolation and characterization of 206 RBD-specific monoclonal antibodies derived from single B cells of eight SARS-CoV-2 infected individuals. We identified antibodies with potent anti-SARS-CoV-2 neutralization activity that correlates with their competitive capacity with ACE2 for RBD binding. Surprisingly, neither the anti-SARS-CoV-2 antibodies nor the infected plasma cross-reacted with SARS-CoV or MERS-CoV RBDs, although substantial plasma cross-reactivity to their trimeric Spike proteins was found. Crystal structure analysis of RBD-bound antibody revealed steric hindrance that inhibits viral engagement with ACE2 and thereby blocks viral entry. These findings suggest that anti-RBD antibodies are viral species-specific inhibitors. The antibodies identified here may be candidates for the development of SARS-CoV-2 clinical interventions.","Nature","Ju, Bin","Zhang, Qi","Ge, Jiwan","Wang, Ruoke","Sun, Jing","Ge, Xiangyang","Yu, Jiazhen","Shan, Sisi","Zhou, Bing","Song, Shuo","Tang, Xian","Yu, Jinfang","Lan, Jun","Yuan, Jing","Wang, Haiyan","Zhao, Juanjuan","Zhang, Shuye","Wang, Youchun","Shi, Xuanling","Liu, Lei","Zhao, Jincun","Wang, Xinquan","Zhang, Zheng","Zhang, Linqi","32454513"],"abstract":["The emerging coronavirus SARS-CoV-2 pandemic presents a global health emergency in urgent need of interventions(1-3). SARS-CoV-2 entry into the target cells depends on binding between the receptor-binding domain (RBD) of the viral Spike protein and the ACE2 cell receptor(2,4-6). Here, we report the isolation and characterization of 206 RBD-specific monoclonal antibodies derived from single B cells of eight SARS-CoV-2 infected individuals. We identified antibodies with potent anti-SARS-CoV-2 neutralization activity that correlates with their competitive capacity with ACE2 for RBD binding. Surprisingly, neither the anti-SARS-CoV-2 antibodies nor the infected plasma cross-reacted with SARS-CoV or MERS-CoV RBDs, although substantial plasma cross-reactivity to their trimeric Spike proteins was found. Crystal structure analysis of RBD-bound antibody revealed steric hindrance that inhibits viral engagement with ACE2 and thereby blocks viral entry. These findings suggest that anti-RBD antibodies are viral species-specific inhibitors. The antibodies identified here may be candidates for the development of SARS-CoV-2 clinical interventions."],"journal":"Nature","authors":["Ju, Bin","Zhang, Qi","Ge, Jiwan","Wang, Ruoke","Sun, Jing","Ge, Xiangyang","Yu, Jiazhen","Shan, Sisi","Zhou, Bing","Song, Shuo","Tang, Xian","Yu, Jinfang","Lan, Jun","Yuan, Jing","Wang, Haiyan","Zhao, Juanjuan","Zhang, Shuye","Wang, Youchun","Shi, Xuanling","Liu, Lei","Zhao, Jincun","Wang, Xinquan","Zhang, Zheng","Zhang, Linqi"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454513","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1038/s41586-020-2380-z","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667881798493798400,"score":484.27423},{"pmid":32425270,"pmcid":"PMC7231725","title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.","text":["Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.","The COVID-19 pandemic urgently needs therapeutic and prophylactic interventions. Here we report the rapid identification of SARS-CoV-2 neutralizing antibodies by high-throughput single-cell RNA and VDJ sequencing of antigen-enriched B cells from 60 convalescent patients. From 8,558 antigen-binding IgG1(+) clonotypes, 14 potent neutralizing antibodies were identified with the most potent one, BD-368-2, exhibiting an IC50 of 1.2 ng/mL and 15 ng/mL against pseudotyped and authentic SARS-CoV-2, respectively. BD-368-2 also displayed strong therapeutic and prophylactic efficacy in SARS-CoV-2-infected hACE2-transgenic mice. Additionally, the 3.8A Cryo-EM structure of a neutralizing antibody in complex with the spike-ectodomain trimer revealed the antibody's epitope overlaps with the ACE2 binding site. Moreover, we demonstrated that SARS-CoV-2 neutralizing antibodies could be directly selected based on similarities of their predicted CDR3H structures to those of SARS-CoV neutralizing antibodies. Altogether, we showed that human neutralizing antibodies could be efficiently discovered by high-throughput single B-cell sequencing in response to pandemic infectious diseases.","Cell","Cao, Yunlong","Su, Bin","Guo, Xianghua","Sun, Wenjie","Deng, Yongqiang","Bao, Linlin","Zhu, Qinyu","Zhang, Xu","Zheng, Yinghui","Geng, Chenyang","Chai, Xiaoran","He, Runsheng","Li, Xiaofeng","Lv, Qi","Zhu, Hua","Deng, Wei","Xu, Yanfeng","Wang, Yanjun","Qiao, Luxin","Tan, Yafang","Song, Liyang","Wang, Guopeng","Du, Xiaoxia","Gao, Ning","Liu, Jiangning","Xiao, Junyu","Su, Xiao-Dong","Du, Zongmin","Feng, Yingmei","Qin, Chuan","Qin, Chengfeng","Jin, Ronghua","Xie, X Sunney","32425270"],"abstract":["The COVID-19 pandemic urgently needs therapeutic and prophylactic interventions. Here we report the rapid identification of SARS-CoV-2 neutralizing antibodies by high-throughput single-cell RNA and VDJ sequencing of antigen-enriched B cells from 60 convalescent patients. From 8,558 antigen-binding IgG1(+) clonotypes, 14 potent neutralizing antibodies were identified with the most potent one, BD-368-2, exhibiting an IC50 of 1.2 ng/mL and 15 ng/mL against pseudotyped and authentic SARS-CoV-2, respectively. BD-368-2 also displayed strong therapeutic and prophylactic efficacy in SARS-CoV-2-infected hACE2-transgenic mice. Additionally, the 3.8A Cryo-EM structure of a neutralizing antibody in complex with the spike-ectodomain trimer revealed the antibody's epitope overlaps with the ACE2 binding site. Moreover, we demonstrated that SARS-CoV-2 neutralizing antibodies could be directly selected based on similarities of their predicted CDR3H structures to those of SARS-CoV neutralizing antibodies. Altogether, we showed that human neutralizing antibodies could be efficiently discovered by high-throughput single B-cell sequencing in response to pandemic infectious diseases."],"journal":"Cell","authors":["Cao, Yunlong","Su, Bin","Guo, Xianghua","Sun, Wenjie","Deng, Yongqiang","Bao, Linlin","Zhu, Qinyu","Zhang, Xu","Zheng, Yinghui","Geng, Chenyang","Chai, Xiaoran","He, Runsheng","Li, Xiaofeng","Lv, Qi","Zhu, Hua","Deng, Wei","Xu, Yanfeng","Wang, Yanjun","Qiao, Luxin","Tan, Yafang","Song, Liyang","Wang, Guopeng","Du, Xiaoxia","Gao, Ning","Liu, Jiangning","Xiao, Junyu","Su, Xiao-Dong","Du, Zongmin","Feng, Yingmei","Qin, Chuan","Qin, Chengfeng","Jin, Ronghua","Xie, X Sunney"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425270","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.cell.2020.05.025","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667252837804933122,"score":481.51495},{"pmid":32405117,"pmcid":"PMC7219369","title":"Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.","text":["Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.","SARS-CoV-2-caused COVID-19 cases are growing globally, calling for developing effective therapeutics to control the current pandemic. SARS-CoV-2 and SARS-CoV recognize angiotensin-converting enzyme 2 (ACE2) receptor via the receptor-binding domain (RBD). Here, we identified six SARS-CoV RBD-specific neutralizing monoclonal antibodies (nAbs) that cross-reacted with SARS-CoV-2 RBD, two of which, 18F3 and 7B11, neutralized SARS-CoV-2 infection. 18F3 recognized conserved epitopes on SARS-CoV and SARS-CoV-2 RBDs, whereas 7B11 recognized epitopes on SARS-CoV RBD not fully conserved in SARS-CoV-2 RBD. The 18F3-recognizing epitopes on RBD did not overlap with the ACE2-binding sites, whereas those recognized by 7B11 were close to the ACE2-binding sites, explaining why 7B11 could, but 18F3 could not, block SARS-CoV or SARS-CoV-2 RBD binding to ACE2 receptor. Our study provides an alternative approach to prevent SARS-CoV-2 infection using anti-SARS-CoV nAbs.","Antiviral Res","Tai, Wanbo","Zhang, Xiujuan","He, Yuxian","Jiang, Shibo","Du, Lanying","32405117"],"abstract":["SARS-CoV-2-caused COVID-19 cases are growing globally, calling for developing effective therapeutics to control the current pandemic. SARS-CoV-2 and SARS-CoV recognize angiotensin-converting enzyme 2 (ACE2) receptor via the receptor-binding domain (RBD). Here, we identified six SARS-CoV RBD-specific neutralizing monoclonal antibodies (nAbs) that cross-reacted with SARS-CoV-2 RBD, two of which, 18F3 and 7B11, neutralized SARS-CoV-2 infection. 18F3 recognized conserved epitopes on SARS-CoV and SARS-CoV-2 RBDs, whereas 7B11 recognized epitopes on SARS-CoV RBD not fully conserved in SARS-CoV-2 RBD. The 18F3-recognizing epitopes on RBD did not overlap with the ACE2-binding sites, whereas those recognized by 7B11 were close to the ACE2-binding sites, explaining why 7B11 could, but 18F3 could not, block SARS-CoV or SARS-CoV-2 RBD binding to ACE2 receptor. Our study provides an alternative approach to prevent SARS-CoV-2 infection using anti-SARS-CoV nAbs."],"journal":"Antiviral Res","authors":["Tai, Wanbo","Zhang, Xiujuan","He, Yuxian","Jiang, Shibo","Du, Lanying"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405117","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.antiviral.2020.104820","keywords":["covid-19","sars-cov","sars-cov-2","cross-neutralization","neutralizing monoclonal antibodies","receptor-binding domain"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666950579820167168,"score":480.41708},{"pmid":32475809,"title":"Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.","text":["Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.","SARS-CoV-2-caused COVID-19 cases are growing globally, calling for developing effective therapeutics to control the current pandemic. SARS-CoV-2 and SARS-CoV recognize angiotensin-converting enzyme 2 (ACE2) receptor via the receptor-binding domain (RBD). Here, we identified six SARS-CoV RBD-specific neutralizing monoclonal antibodies (nAbs) that cross-reacted with SARS-CoV-2 RBD, two of which, 18F3 and 7B11, neutralized SARS-CoV-2 infection. 18F3 recognized conserved epitopes on SARS-CoV and SARS-CoV-2 RBDs, whereas 7B11 recognized epitopes on SARS-CoV RBD not fully conserved in SARS-CoV-2 RBD. The 18F3-recognizing epitopes on RBD did not overlap with the ACE2-binding sites, whereas those recognized by 7B11 were close to the ACE2-binding sites, explaining why 7B11 could, but 18F3 could not, block SARS-CoV or SARS-CoV-2 RBD binding to ACE2 receptor. Our study provides an alternative approach to prevent SARS-CoV-2 infection using anti-SARS-CoV nAbs.","Antiviral Res","Tai, Wanbo","Zhang, Xiujuan","He, Yuxian","Jiang, Shibo","Du, Lanying","32475809"],"abstract":["SARS-CoV-2-caused COVID-19 cases are growing globally, calling for developing effective therapeutics to control the current pandemic. SARS-CoV-2 and SARS-CoV recognize angiotensin-converting enzyme 2 (ACE2) receptor via the receptor-binding domain (RBD). Here, we identified six SARS-CoV RBD-specific neutralizing monoclonal antibodies (nAbs) that cross-reacted with SARS-CoV-2 RBD, two of which, 18F3 and 7B11, neutralized SARS-CoV-2 infection. 18F3 recognized conserved epitopes on SARS-CoV and SARS-CoV-2 RBDs, whereas 7B11 recognized epitopes on SARS-CoV RBD not fully conserved in SARS-CoV-2 RBD. The 18F3-recognizing epitopes on RBD did not overlap with the ACE2-binding sites, whereas those recognized by 7B11 were close to the ACE2-binding sites, explaining why 7B11 could, but 18F3 could not, block SARS-CoV or SARS-CoV-2 RBD binding to ACE2 receptor. Our study provides an alternative approach to prevent SARS-CoV-2 infection using anti-SARS-CoV nAbs."],"journal":"Antiviral Res","authors":["Tai, Wanbo","Zhang, Xiujuan","He, Yuxian","Jiang, Shibo","Du, Lanying"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32475809","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.antiviral.2020.104820","keywords":["covid-19","cross-neutralization","neutralizing monoclonal antibodies","receptor-binding domain","sars-cov","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668532089526419456,"score":480.41708}]}